Interesting report on targetable fusions in KRAS WT #PancreaticCancer. I often find that therapeutic nihilism prevents sequencing of these patients, but recent data supports that, although rare, actionable alterations are present (thread) https://ascopubs.org/doi/full/10.1200/PO.20.00265#.YC58HoDaupY.twitter
We already knew gene fusions are enriched in KRAS WT #PancreaticCancer. I point to this very elegant analysis in which 3 patients with NRG1 fusions were identified, and 2 received targeted therapy with benefit https://clincancerres.aacrjournals.org/content/25/15/4674.long
There's also data on NTRK fusions in pancreatic cancer. In this matter, a very intriguing case report by @EileenMOReilly was published at @Annals_Oncology; patient had initial benefit from larotrectinib but eventually progressed https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6859823/